Will Coronavirus herald a new era in vaccine innovation?

Kanopi

As this novel coronavirus continues to spread, and the number of people infected with COVID-19 keeps rising, the race is on to develop a vaccine. But the time it takes to carry out clinical trials, to ensure that a vaccine is both safe and effective, means this won’t happen overnight.

However, with at least 35 coronavirus vaccines now being developed, even compared to recent pandemics, we have new tools available that could help us reach that goal in record time.

Read more on the Gavi website here.

You May Also Like

Linked Community News June 2024

This newsletter is available in English, Portuguese, Spanish, and Russian. We’re kicking off June with exciting network updates and the latest evidence from the global immunisation community. At the end of May, Linked held a two-day kickoff meeting in Jakarta for the new Indonesia Subnational Peer-to-Peer Learning Platform. Immunisation practitioners, policymakers, and partners working at … Read More

Immunization Delivery Cost Catalogue update: The state of the evidence on the cost of delivering immunisation in low- and middle-income countries

ThinkWell is pleased to present an updated version of the Immunization Delivery Cost Catalogue, or IDCC, the most comprehensive, current, and standardized database on the cost of delivering vaccines in low- and middle-income countries. Based on a systematic review of over 22,000 publications, the updated IDCC presents 1,156 unique unit costs from 119 publications, in … Read More

Launch of the new immunizationeconomics.org website including resource library

The Immunization Economics Community of Practice management team are excited to announce the launch of the new website. With this refresh, it is easier for users to find resources and navigate the website. You can now find a resource library in which every immunization economics resource ever published can easily individually be found through a … Read More